Knockdown of Latent Transforming Growth Factor-β (TGF-β)-Binding Protein 2 (LTBP2) Inhibits Invasion and Tumorigenesis in Thyroid Carcinoma Cells
-
- Fuqiang Wan
- Department of Head and Neck Surgery, Linyi Tumor Hospital, Linyi, P.R. China
-
- Li Peng
- Department of Head and Neck Surgery, Linyi Tumor Hospital, Linyi, P.R. China
-
- ChaoYu Zhu
- Department No. 2 of Abdominal Surgery, Linyi Tumor Hospital, Linyi, P.R. China
-
- XinFa Zhang
- Department of Breast Surgery, Linyi Tumor Hospital, Linyi, P.R. China
-
- FangWen Chen
- Department of Head and Neck Surgery, Linyi Tumor Hospital, Linyi, P.R. China
-
- Tao Liu
- Department of General Surgery, Linyi People’s Hospital, Linyi, P.R. China
この論文をさがす
説明
<jats:p>Latent transforming growth factor-β (TGF-β)-binding protein 2 (LTBP2) is one of four proteins in the LTBP family of proteins (LTBP1‐4) and was shown to play a vital role in tumorigenesis. However, little is known regarding the functional role of LTBP2 in thyroid carcinoma. Therefore, the current study aimed to evaluate the effect of LTBP2 expression on the proliferation, invasion, and tumorigenesis in thyroid carcinoma cells and to explore the molecular mechanism of LTBP2 in tumor progression. Our results showed that the expression of LTBP2 is upregulated in human thyroid carcinoma and cell lines. Knockdown of LTBP2 inhibits the proliferation, invasion, and EMT phenotype in thyroid carcinoma cells. Furthermore, knockdown of LTBP2 attenuates thyroid carcinoma growth in nude mice. Finally, knockdown of LTBP2 inhibits activation of the PI3K/Akt pathway in thyroid carcinoma cells. In summary, the present study has provided further evidence that knockdown of LTBP2 inhibits invasion and tumorigenesis in thyroid carcinoma cells. Our findings may help to further elucidate the molecular mechanisms underlying thyroid carcinoma progression and provide candidate targets for the prevention and treatment of thyroid carcinoma.</jats:p>
収録刊行物
-
- Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
-
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics 25 (4), 503-510, 2017-04-14
Tech Science Press